Potassium Citrate Granules

Pharmacological tests have shown that diluting 2g of potassium citrate granules into 20ml of solution and gavaging mice at 5ml/kg, 10ml/kg, and 20ml/kg respectively can increase the serum potassium content of mice, so it can be used as a potassium supplement. Potassium is the main cation in cells, with a concentration of 150-160mmol/L, while the main cation outside cells is Na+, with a potassium concentration of only 3.5-5.0mmol/L. The body mainly relies on Na+, K+, and ATPase on the cell membrane to maintain the difference in K+ and Na+ concentrations inside and outside cells. The acid-base balance in the body has an impact on potassium metabolism. For example, when acidosis occurs, H enters the cell. In order to maintain the potential difference between the inside and outside of the cell, K+ is released outside the cell, causing or aggravating hyperkalemia. Metabolic disorders can also affect

The main ingredient of this product is potassium citrate, and its chemical name is: potassium 2-hydroxypropane-1,2,3-tricarboxylate monohydrate.

This product is milky yellow crystalline granules or powder; it has a fruity aroma; it tastes sweet and sour with a slightly salty taste; it is soluble in water.

1. Treatment of hypokalemia. Hypokalemia caused by various reasons, such as insufficient food intake, vomiting, severe diarrhea, use of potassium-excreting diuretics, hypokalemic familial periodic paralysis, long-term use of glucocorticoids and supplementation of hypertonic glucose, etc. 2. Prevention of hypokalemia. When patients have potassium loss, especially if hypokalemia is harmful to patients (such as patients taking digitalis drugs), preventive potassium salt supplementation is required. Such as eating very little, severe or chronic diarrhea, long-term use of adrenocortical hormones, potassium-losing nephropathy, Bartter syndrome, etc. 3. Digitalis poisoning causes frequent, multi-source premature beats or rapid arrhythmias.

Oral administration: 1-2 packets each time, 3 times a day, dissolved in warm water and taken.

1 Oral administration may cause gastrointestinal irritation symptoms, such as nausea, vomiting, throat discomfort, chest pain (esophageal irritation), abdominal pain, diarrhea, and even peptic ulcer and bleeding. It is more likely to occur on an empty stomach, in large doses, or in patients with existing gastrointestinal diseases. 2 Hyperkalemia should be noted in patients with existing renal impairment.

1. Contraindicated in patients with hyperkalemia. 2. Contraindicated in patients with heart failure or severe myocardial damage. 3. Contraindicated in patients with peptic ulcer.

Precautions for children: Children should pay attention to electrolyte and acid-base balance after using this product. Precautions for pregnancy and lactation: Pregnant and lactating women should use with caution. Precautions for the elderly: The kidneys of the elderly have a decreased ability to clear potassium, and the use of this product is more likely to cause hyperkalemia, so it should be used with caution. The elderly should also pay attention to electrolyte and acid-base balance when using this product.

1. Adrenal glucocorticoids, especially those with more obvious mineralocorticoid effects), adrenal mineralocorticoids and adrenocorticotropic hormone (ACTH), can promote urinary potassium excretion, and when used together, the efficacy of potassium salts is reduced. 2. Anticholinergic drugs can aggravate the gastrointestinal irritation of oral potassium salts, especially potassium chloride. 3. Non-steroidal anti-inflammatory analgesics aggravate the gastrointestinal reactions of oral potassium salts. 4. When using stored blood (30mmol/L of potassium if stored for less than 10 days, 65mmol/L of potassium if stored for more than 10 days), potassium-containing drugs and potassium-sparing diuretics together, the chance of hyperkalemia increases, especially in patients with renal damage. 5. Angiotensin

Keep sealed.

1.46g/2g

24 months

Changchun Beihua Pharmaceutical Co., Ltd.

• Founded in:

  1986-08-04

• Address:

  Factory No. 5, Changzhou Street New Materials Industrial Park, Xinglong Free Trade Zone, Changchun City

• Tax NO.:

  912201017493282511

• Registered Funds:

  60 million yuan

• Email:

  Log in to view